The Negative Effects of Mounjaro: What the Evidence Actually Shows

What the trial data found: how common are side effects?

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across 72 weeks. Gastrointestinal reactions were the most frequently reported events across all tirzepatide doses. Nausea was the most common single effect, followed by diarrhoea, vomiting, constipation, indigestion and burping. The key finding (often glossed over) is that the large majority of these events were mild to moderate in intensity, and most occurred during dose escalation rather than persisting throughout treatment.

This pattern is consistent with how tirzepatide works: it slows the movement of food through the stomach, which helps reduce appetite but can also cause digestive discomfort while the body adapts. Once you reach a stable dose, the gut usually catches up. A practical check you can do in under a minute: look at whether your symptoms started or worsened in the few days after a dose increase. If so, that's typical timing. If they appear out of nowhere mid-dose-period, it's worth contacting your prescriber.

For a broader picture of how tirzepatide behaves in the body, the effects of tirzepatide page covers the full mechanism alongside the benefits and risks together.

Serious effects that need urgent attention

Most of what people experience is uncomfortable rather than dangerous. But a minority of effects are serious, and the NHS is clear that some require prompt medical help rather than a wait-and-see approach.

Acute pancreatitis sits at the top of that list. The MHRA's January 2026 Drug Safety Update (which you can read at the MHRA Drug Safety Updates index) flagged pancreatitis as a known risk across GLP-1 medicines including tirzepatide. The warning sign to act on immediately is severe stomach pain that comes on suddenly, persists, and may spread to the back, with or without vomiting. This is not the garden-variety nausea of a dose increase. Go to A&E or call 999 if you experience it.

Other effects that require a conversation with a doctor rather than waiting include: signs of a gallbladder problem (sharp pain under the right side of the ribs), symptoms of severe dehydration from prolonged vomiting or diarrhoea (dizziness, very dark urine, inability to keep fluids down), and any allergic reaction such as swelling, hives or breathing difficulty. Some people report changes in mood or low mood. Tell your prescriber about this promptly. It is worth reading the serious effects of Mounjaro page for a fuller account of these warning signals.

Effects that are less talked about but worth knowing

Beyond the standard GI list, there are a handful of reported effects that tend to surprise people. Fatigue and headache feature in the trial data, particularly in the early weeks. Hair thinning sometimes occurs a few months into significant weight loss — this is not unique to Mounjaro and is thought to relate to the physiological stress of rapid body-composition change rather than the drug directly, though it is worth mentioning to your prescriber.

Some patients raise questions about other effects they've noticed, including changes they wouldn't immediately associate with a weight-loss medicine. The Mounjaro and vaginal dryness page addresses one such question with the current evidence. Our FAQs cover others.

Injection-site reactions (redness, mild bruising or itchiness at the injection point) are also documented, though generally minor. Rotating the injection site between the abdomen, thigh and upper arm reduces the chance of them building up in one area. The NHS tirzepatide medicines page lists the full side-effect profile at a patient-accessible level and is a reliable starting point for any effect you can't find covered elsewhere.

How the risk picture applies to you personally

Trial populations give us probabilities across thousands of people, not predictions about any individual. Whether a specific effect is likely for you depends on your health history, existing conditions and other medicines, which is exactly why tirzepatide requires a clinical assessment rather than a straightforward purchase. Some contraindications are absolute: it is not licensed for use under 18, in pregnancy, or while breastfeeding. People with a personal or close family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take it; if you want to understand the negatives of Mounjaro before starting, including these contraindications, that page sets them out clearly. Before committing to treatment, it can also help to review the full range of Mounjaro effects, both the intended benefits and the documented risks, so you can weigh them against your personal health goals. Those who are already on the medicine may find it equally useful to read about the after effects of Mounjaro, covering what to expect once a course of treatment ends.

Cost is occasionally part of the picture too, some people want to understand the trade-offs before committing. Our weight-loss treatment overview sets the broader context, and the consultation page is where a prescriber can go through your specific history with you. If you have questions that aren't covered here, the contact page reaches the aftercare team seven days a week.

Reporting suspected side effects (including any you're uncertain about) can be done directly through the MHRA's Yellow Card scheme. It takes a few minutes and genuinely helps build the safety record for medicines still under active monitoring.